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BACKGROUND: Protein tyrosine kinase 6 (PTK6; breast tumour kinase) is overexpressed in up to 86% of the invasive breast cancers,
and its association with the oncoprotein human epidermal growth factor receptor 2 (HER2) was shown in vitro by co-precipitation.
Furthermore, expression of PTK6 in tumours is linked with the expression of HER2.
METHOD AND RESULTS:In this study, we used the proximity ligation assay (PLA) technique on formalin-fixed paraffin sections from eighty
invasive breast carcinoma tissue specimens to locate PTK6–HER2 protein–protein complexes. Proximity ligation assay signals from
protein complexes were assessed quantitatively, and expression levels showed a statistically significant association with tumour size
(P¼0.015) and course of the cancer disease (P¼0.012).
CONCLUSION: Protein tyrosine kinase 6 forms protein complexes with HER2 in primary breast cancer tissues, which can be visualised
by use of the PLA technique. Human epidermal growth factor receptor 2–PTK6 complexes are of prognostic relevance.
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Although cytoplasmic protein tyrosine kinase 6 (PTK6; breast
tumour kinase (BRK)) is overexpressed in up to 86% of breast
carcinomas (Ostrander et al, 2007; Harvey et al, 2009; Brauer
and Tyner, 2010), its physiological role is rather unclear. How-
ever, various in vitro studies have suggested its possible involve-
ment in modulating signal transduction of human epidermal growth
factor receptor (HER) tyrosine kinases (Haegebarth et al,2 0 0 5 ;
Zhang et al, 2005; Ostrander et al, 2007; Aubele et al, 2008), as well as
influencing transcriptional activities (Liu et al, 2006; Weaver and
Silva, 2007) and proliferation (Harvey and Crompton, 2003). Using
immunohistochemistry on breast cancer tissues, PTK6 expression
was shown to be associated with the expression of HER receptors
(Aubele et al, 2007, 2008; Xiang et al, 2008), and with the course of
the breast cancer disease (Aubele et al, 2007).
In this study, we applied the proximity ligation assay (PLA)
technique (So ¨derberg et al, 2006), to examine the presence of
PTK6–HER2 protein–protein interactions in 80 primary invasive
breast carcinoma tissue specimens. As a result, we give evidence
that PTK6–HER2 protein complex formation is associated with
tumour size and patient outcome.
MATERIALS AND METHODS
Transfection of T47D cells
A total of 10
6 T47D cells growing in antibiotic-free RPMI medium
(Aubele et al, 2008) were transfected with Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) and siRNAs (each 200pmol,
Thermo Scientific, Dharmacon, Chicago, IL, USA) targeting PTK6
and HER2, respectively, according to the manufacturers’ instruc-
tions. As controls, we added transfection reagents without siRNAs
to the control cells (mock transfection), and performed transfec-
tion of the control cells with siRNA targeting GAPDH. After 24h,
one part of the cells was further cultivated in complete medium
for 48h and then used for protein isolation and western blot
analysis. The other part of cells was placed on microscopic
slides (2.5 10
5 cells per slide; SuperFrost, Carl Roth, Karlsruhe,
Germany) and further cultivated for 48h. Subsequently, the slides
were washed in PBS and fixed with 4% paraformaldehyde for
15min at 221C.
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T47D cells were washed in PBS, sedimented, and lysed as described
previously (Aubele et al, 2008). Then, PTK6, HER2, and GAPDH
protein expressions were detected by primary antibodies against
PTK6 (sc-1188, Santa Cruz, Biotech, Heidelberg, Germany),
GAPDH (sc-25778, Santa Cruz Biotech, Heidelberg, Germany),
HER2 (A0485, DAKO, Glostrup, Denmark), and tubulin
(T5168, Sigma, St Louis, MO, USA) as loading control.
Peroxidase-conjugated secondary antibodies were added
(NA934V and NA931V; GE Healthcare, Chalfont St Giles,
Buckinghamshire, UK). Band intensities were quantified densito-
metrically relative to the appropriate control bands using the
Molecular Imager ChemiDoc XRS and the software Quantity One
(Bio-Rad Laboratories, Hercules, CA, USA).
Patients and tumour samples
Tumour samples from 80 patients were randomly selected, and all
tumour patients were surgically treated. None of the patients
received any preoperative treatment, and there was no correlation
between the adjuvant treatment regimes and our results. The
median time of follow-up of patients was 139 months (maximum
252 months) with 24 (30%) of the patients experiencing distant
disease recurrences. Further information of the samples is
summarised in Table 1. For all of the patients, the immuno-
histochemical data for HER2 status (Hercep test, K5204, DAKO,
Hamburg, Germany) and for PTK6 expression (BRK, sc-1188,
Santa Cruz, Biotech, Heidelberg, Germany) were available as
published elsewhere (Aubele et al, 2008).
Proximity ligation assay technique
From tissue microarray (TMA), blocks containing primary
breast cancer tissues of (Aubele et al, 2007) 5mm thick sections
were cut, deparaffinised, and subjected to antigen retrieval by
microwave cooking in 0.01M citrate buffer (pH 6.0) at 1000W for
30min. From here on the TMA sections and the T47D cells were
treated identically. After blocking (purchased by Olink Bioscience,
Uppsala, Sweden) the following primary antibodies were used:
for PTK6 (BRK, anti-rabbit, sc-1188, Santa Cruz Biotech,
Heidelberg, Germany, 1:50); for HER2 (Novocastra, anti-mouse,
NCL-L-CB11, 1:7). The PLA protocol was followed according
to the manufacturers’ instructions (Olink Bioscience, Uppsala,
Sweden), with incubation of the primary antibodies at 41C over
night. Proximity ligation assay minus and PLA plus probes
(containing the secondary antibodies conjugated with oligonucleo-
tides) were added and incubated 2h at 371C. Afterwards, further
oligonucleotides are added, allowed to hybridise to the
PLA probes, and ligase joins the two hybridised oligonucleotides
to a closed circle. The DNA is then amplified (rolling circle
Table 1 Histopathological parameters of the tumours
Parameter Number of patients
Lymphnode status 0/+ 51, 29
Tumour size
o2cm,X2o5cm,X5cm 58, 20, 2
Histological grade
a
(1, 2, 3) 13, 42, 25
Histological type
Invasive ductal 67
Lobular 7
Else 6
Estrogen receptor
Negative, low, high 20, 27, 33
Progesterone receptor
Negative, low, high 38, 17, 25
IHC-HER2
0/1+ 56
2+/3+ 24
IHC-PTK6
0/1+ 28
2+/3+ 52
Abbreviations: HER2¼human epidermal growth factor receptor 2; IHE¼immuno
histochemistry; PTK6¼protein tyrosine kinase 6.
aGrading according to Elston and
Ellis (1991).
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Figure 1 Protein tyrosine kinase 6–HER2 complex formation in T47D cells as visualised by the PLA technique. Control T47D cells (A, C) and T47D cells
after siRNA-mediated down-regulation of PTK6 (B) or HER2 (D). Western blot analysis of proteins extracted from T47D cells after transfection with siRNA
targeting PTK6 (E) and HER2 (F), respectively; control cells were treated with transfection reagents only or with siRNA targeting GAPDH;
(tubulin¼loading control).
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using the ‘563 detection kit’ (including Hoechst 33342 dye nuclear
staining), resulting in red fluorescence signals. The sections were
mounted with Vectashield mounting media (Vector Lab., Inc.,
Burlingame, CA, USA).
Image acquisition and evaluation of signal counts
The hybridised slides were viewed under a confocal laser scanning
microscope (AxioImager, Zeiss, Jena, Germany) equipped with the
Apotome Extension (Zeiss Vision, Jena, Germany) and appropriate
filters (signals: 563/581nm, nuclei: 352/455nm excitation/emis-
sion). Within each tissue spot optical sections were captured from
three to five different tumour areas at a distance of 0.3mm using a
C-Apochromat   63/1.2 W objective. Three-dimensional image
projections were calculated (AxioVision software, Zeiss, Jena,
Germany), converted to TIF format, and signals from protein
complexes were evaluated using the Definiens Enterprise Image
Intelligence Suite software (Definiens, Munich, Germany). A
specific rule set was defined to detect and quantify semantic
classes (‘signal’ and ‘nucleus’), based on fluorescence layer,
intensity, and shape. Finally, for each image the mean number of
protein complex signals (mean PLA) was calculated per 1000 pixels
of tissue area, and subjected to statistical evaluation.
Statistics
Correlations among the mean PLA signal counts and the
immunohistochemical and histopathological parameters were
examined by Spearman’s rank correlation test. For univariate
survival analysis, Kaplan–Meier curves were calculated for distant
metastasis-free survival of patients, and differences between the
groups were tested with the log-rank w
2 value. Multivariate analysis
was carried out using Cox proportional hazards regression and
a combined stepwise selection algorithm (SAS Inst., Cary, NC,
USA). All parameters reaching a significance level of Pp0.15 in
univariate analysis were offered to multivariate analysis. In all,
other tests statistical significance was considered proven if
Pp0.05.
PLA PTK6-IHC HER2-IHC
Figure 2 Examples for PLA on tumour tissue sections showing PLA results and the corresponding results obtained by immunohistochemical staining of
PTK6 and HER2. Strong staining for HER2 (3þ, A) and PTK6 (2þ, B) resulted in high signal counts of protein complexes (C); weak positivity for both
proteins (HER2: 1þ, D; PTK6: 1þ, E) resulted in low signal count (F). Further examples are given for HER2 high (G) / PTK6 low (H) expression and for
HER2 low (J) / PTK6 high (K) expression, both resulting in rare PLA signals (I, L).
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Down-regulation of PTK6 and HER2 proteins in T47D
cell line
The need for presence of both, HER2, and PTK6 proteins for
detection of PTK6–HER2 protein complexes, was proven by using
T47D cells, which slightly overexpress both, HER2 and PTK6.
Proximity ligation assay was carried out after down-regulation of
PTK6 and HER2, respectively, using specific small interfering
RNAs (siRNAs). As shown in Figure 1, cells transfected with siRNA
showed significantly reduced signal counts when compared with
the non-transfected control cells. These results are corroborated
by western blot analysis (Figure 1E, F) showing PTK6 and HER2
down-regulation after siRNA transfection to 21 and 49% of
untreated controls, respectively.
Visualisation and statistical evaluation of PTK6–HER2
protein complexes in tumour tissue
Eighty primary invasive breast carcinomas were analyzed using the
PLA technique, using primary antibodies against both HER2 and
PTK6 proteins. The mean number of PLA signals detected in all
of the cases was compared with the data obtained by immuno-
histochemistry for PTK6 and HER2, and with the histopathological
data and the clinical course of patients. Examples of PLA
on tumour tissue specimens are shown in Figure 2 together
with corresponding images from PTK6 and HER2 immunohisto-
chemistry.
From the histopathological parameters (tumour size, lymph-
node status, histological grade, oestrogen, and progesterone
receptor status), only tumour size was significantly correlated
(P¼0.015) with the mean number of PLA signals. The IHC from
HER2 (P¼0.19) and PTK6 (P¼0.1) were not significantly
associated with the PLA signal counts.
With respect to the distant metastasis-free survival (univariate)
the mean PLA signals showed a significant univariate association
with distant metastasis-free survival of patients. As shown in
Figure 3, low signal counts (p0.5 per 1000 pixels of tumour area,
n¼48 patients) were associated with better prognosis with 20.8%
of patients with distant metastasis, whereas from the patients
with 40.5 signals (n¼28) 50% suffer from metastasis (P¼0.012).
Furthermore, IHC-PTK6 (P¼0.018, inverse), tumour size
(P¼0.01), and lymph node status (P¼0.004) were also significant
in univariate analysis, whereas no significance level was reached by
IHC-HER2 (P¼0.35), ER (P¼0.9), and PrR (P¼0.36).
Although the number of tumours is very small, we carried
out multivariate analysis offering all parameters significant in
univariate analysis: the prognostic value of the lymphnode status
(P¼0.008) was further improved by IHC-PTK6 (P¼0.006) and by
the mean PLA signals (P¼0.01).
DISCUSSION
The function of PTK6 remains poorly understood. Protein tyrosine
kinase 6 has been linked to cell differentiation, growth regulation,
and apoptosis (Harvey and Crompton, 2003; Brauer and Tyner,
2010), and there is increasing evidence that it interacts with HER
receptors (Kamalati et al, 1996, 2000; Chen et al, 2004; Haegebarth
et al, 2005; Aubele et al, 2008; Xiang et al, 2008) and downstream
signalling molecules (Zhang et al, 2005; Ostrander et al, 2007;
Aubele et al, 2008). So far, PTK6 interacting proteins were
identified in in vitro studies using immunoprecipitation and
western blot analysis. In breast cancer tissue significant correlation
was identified between the expression levels of PTK6 and HER2
(Born et al, 2005; Aubele et al, 2007, 2008; Xiang et al, 2008).
Thus, potentially, PTK6 may represent a therapeutic target in
clinical management of breast cancer in addition to the established
anti-HER2 therapy with the humanised antibody trastuzumab,
which targets HER2, but progression is common within 1 year
(Nahta and Esteva, 2007).
The PLA technique enables accurate visualisation, subcellular
localisation, and quantitative evaluation of protein–protein
interactions, as, for example, was shown for complexes of prostate
specific antigen with a1-protease inhibitor (Zhu et al, 2009), and
for EGF receptor–HER2 complex formation in vitro (Leuchowius
et al, 2009).
In this study, we used the PLA technique to show for the first
time ever that PTK6 forms protein complexes with HER2 in
paraffin tissues from invasive breast carcinomas. Our results on
tumour tissues are corroborated by down-regulation of each of
these proteins in T47D cell line, resulting in reduced PLA signal
counts. In tumour tissues, we identified significant correlation of
PLA signals with tumour size and with distant metastasis-free
survival of patients. In the context of our previous findings, in
which PTK6 expression was shown to be linked to a better
prognosis, the correlation of PTK6–HER2 protein complexes with
occurrence of metastasis seems to be inconsistent. However,
the associations of HER2 with bad prognosis (P¼0.35) and of
PTK6 with good prognosis (P¼0.018, inverse correlation) were
confirmed in this study. The association of the mean PLA signals
with bad prognosis may be explained by the fact that PLA
signals do not necessarily reflect the expression of the single
proteins, but represent a feature independent from the single
protein expressions.
Our findings show that HER2–PTK6 protein complexes are
of prognostic value and that PTK6 may be considered as additional
breast cancer biomarker and potential target for anticancer
therapy.
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Figure 3 Kaplan–Meier survival curves illustrating probability of distant
metastasis-free survival of breast cancer patients according to their HER2–
PTK6 protein complex status. Patients with low PLA signals (p0.5, solid
line) are associated with better prognosis (21% of patients developed
distant metastases), whereas from patients with higher PLA signal counts
(40.5, dashed line) 50% suffer from distant metastases. (Mean PLA was
defined as mean number of PLA signals per 1000 pixels of tumour area in
the section).
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